Merck KGaA is well positioned to navigate the challenges thrown up by "a highly dynamic geopolitical situation," declared CEO Belén Garijo after presenting a solid set of financials for the first quarter.
Merck KGaA Well-Equipped Against War And Raw Material Shortages
Healthcare Sales Strong In Q1
Despite the impact of the war in Ukraine and spiralling costs, as well as lower COVID-19-based revenues, the German group is forecasting a healthy financial performance for full-year 2022.
More from Earnings
More from Business
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.